We have found that EMX2OS, which has been expressed in ovarian cancer, may inhibit tumor development and development by acting on PD-L1 (procedural cell death protein 1) through the EMX2OS/miR-654/AKT3 axis (Duan et al., 2020). Here, AKT3 is linked to neoplasm.